Back to search results

Study of JNJ-90301900 for Non-Small Cell Lung Cancer

This study is investigating if adding JNJ-90301900 to standard treatment can improve outcomes for people with locally advanced non-small cell lung cancer (NSCLC). The standard treatment includes chemotherapy (Carboplatin and Paclitaxel) and radiation therapy, followed by immunotherapy (Durvalumab). JNJ-90301900 will be injected into the tumor or lymph nodes. The study is looking to see if more participants have their tumors shrink or disappear (objective response rate) when JNJ-90301900 is added. You may be able to join if you are an adult (18 years or older) and are a candidate for this standard treatment for NSCLC. The study plans to enroll 130 participants, but its current status is unclear.

Study design
This is an interventional study with a planned enrollment of 130 participants. The phase of the study is not specified.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome, objective response rate, will be measured for up to 2 years and 2 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06667908

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

Recruiting
PHASE2Ages 18+InterventionalTreatment
Johnson & Johnson Enterprise Innovation Inc.
~130 participants
Updated 2026-08-28 on ClinicalTrials.gov
What's tested:JNJ-90301900DurvalumabConcurrent Chemo/Radiation Therapy (cCRT)Concurrent Chemo/Radiation Therapy (cCRT): CarboplatinConcurrent Chemo/Radiation Therapy (cCRT): Paclitaxel

At a glance

Recruiting sites
43 of 43 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Objective Response Rate (ORR) Using Independent Central Review (ICR) Assessment
Measured over Up to 2 Years and 2 months

Conditions

Carcinoma, Non-Small-Cell Lung

Explore related trials

Lung Non-Small Cell Carcinoma

Where it's being run

43 sites across 23 states
France5
Australia4
Spain4
Brazil3
China3
Connecticut2
Florida2
New York2

Study leadership

  • Johnson & Johnson Enterprise Innovation Inc. Clinical Trial · STUDY_DIRECTOR · Johnson & Johnson Enterprise Innovation Inc.

Who to contact

Study Contact
[email protected]
844-434-4210
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Must be a candidate for standard of care (SOC) treatment of non small cell lung cancer (NSCLC) by concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation durvalumab treatment as determined by the investigator and per local guidelines at screening
Have a medical history of pathologically (histologically or cytologically) proven diagnosis of NSCLC within 3 months prior to enrollment/randomization
Have locally advanced unresectable stage III NSCLC according to the eighth edition lung cancer stage classification
Have at least 1 target lesion (primary lung lesion or involved lymph node\[s\]) per RECIST version 1.1 that is amenable to intratumoral and/or intranodal injection and intensity modulated radiation therapy (IMRT) as determined by the investigator at screening
Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1

Exclusion

Medical history of: (a) Primary immunodeficiency (b) Organ transplant that requires therapeutic immunosuppression
Any of the following within 3 months prior to enrollment/randomization: severe or unstable angina, myocardial infarction, clinically significant ventricular arrhythmias or heart failure New York heart association functional classification class III to IV
Another concurrent or prior primary malignancy within the last 36 months at informed consent
Known allergies, hypersensitivity, or intolerance to any ingredients of JNJ-90301900 crystalline solution, platinum-based doublet chemotherapy (ChT), or durvalumab
History of coagulation disorders, including: (a) Active bleeding diathesis or requirement for therapeutic anticoagulation or antiplatelet that cannot be interrupted or altered for JNJ-90301900 injection procedures, (b) Major thromboembolic events (for example, pulmonary embolism, cerebrovascular accident) within 3 months of enrollment or randomization

What this trial measures

  • Objective Response Rate (ORR) Using Independent Central Review (ICR) AssessmentUp to 2 Years and 2 months

    ORR is defined as the percentage of participants who have a best response of complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors (RECIST) version (v) 1.1 using ICR assessments.